TP53 and cancer: Such indirect action, dependent on multiple unpredictable circumstances, could explain why missense TP53 mutations are pervasively selected in tumors, but depletion of mutp53 in cancer cell lines and preclinical models gives variable and often contradictory results (Kennedy and Lowe, 2022; Wang et al., 2022).